Prostatype Genomics AB

PROGEN · Nasdaq Stockholm · Healthcare

0.09SEK +1.3%last day

Price as of 2 October 2026

The price over the past year, with dividends: −83.4%

Performance

1 month

−35.6%

1 year

−83.4%

3 years, per year

−89.9%

5 years, per year

−84.2%

Largest fall, 3 years

−99.9%

Below the peak now

−100.0%

Volatility, 1 year

200.1%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

0.8

Dividend yield

0.0%

Return on equity

−167.7%

Net margin

–

Market value

1 m USD

Quality, value and trend

Where Prostatype Genomics stands against every Nordic stock today. 100 is best.

Quality22

Profitability and a sound balance sheet over time. Better than 22% of Nordic stocks.

Value51

The price measured against earnings, assets and cash flow. Better than 51% of Nordic stocks.

Trend1

The price development over the past year. Better than 1% of Nordic stocks.

Combined8

Quality, value and trend together. Better than 8% of Nordic stocks.

About Prostatype Genomics

Prostatype Genomics AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 7 employees.

Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score. Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Nacka, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis